UBS analyst Eliana Merle raised the firm’s price target on BioNTech (BNTX) to $117 from $115 and keeps a Neutral rating on the shares. The Pumitamig data update in first-line treatment for small cell lung cancer has de-risked the pipeline, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNTX:
- BioNTech’s Earnings Call: Progress Amid Challenges
- BioNTech SE: Strong COVID-19 Vaccine Revenues and Pipeline Diversification Drive Buy Rating
- BioNTech price target raised to $134 from $130 at BofA
- BioNTech SE Reports Q3 2025 Financial Results
- BioNTech price target raised to $134 from $131 at Morgan Stanley